Financial Data and Key Metrics Changes - The company ended 2025 with approximately $24.7 million in cash and cash equivalents and working capital of approximately $3.4 million [31] - Selling, general and administrative (SG&A) expenses for 2025 were $8.8 million, a decrease from $9.2 million in 2024, primarily due to lower stock-based compensation and personnel costs [32] - Research and development (R&D) expenses were reported at $5.5 million for 2025, down from $14.3 million in 2024, with contra-R&D expenses reflecting grant dollars received at $13.9 million in 2025 compared to $7.7 million in 2024 [32][33] Business Line Data and Key Metrics Changes - The company is advancing multiple programs simultaneously, including DARE to PLAY, which is expected to begin generating revenue in Q2 2026 [33] - DARE to RESTORE products, including Flora Sync LF5, are expected to be commercially available in the U.S. consumer health market in the second quarter of 2026 [16][27] - DARE to RECLAIM is targeting 503B commercial availability in 2027, while Ovaprene is in a phase III pivotal trial with enrollment expected to complete in 2026 [18][20][27] Market Data and Key Metrics Changes - The company is addressing a significant market gap in women's health, which has historically received only 6% of private healthcare investment, with conditions affecting women attracting less than 1% [25][30] - The estimated market for DARE to RECLAIM is between $2.5 billion and $4.5 billion, targeting the compounded hormone therapy market [18] - The company is also developing DARE-HPV, which addresses a large untreated patient population with high-risk HPV infections, representing a significant market opportunity [22][24] Company Strategy and Development Direction - The company employs a dual-path strategy, commercializing proprietary formulations through 503B compounding while pursuing FDA approval for select products [2][14] - The focus is on building a comprehensive pipeline of differentiated products for women's health, addressing various conditions from contraception to menopause [5][15] - The company aims to leverage non-dilutive funding to advance its programs while managing shareholder dilution responsibly [31][33] Management's Comments on Operating Environment and Future Outlook - Management believes that 2026 will be a pivotal year for the company, showcasing the results of a decade of commitment to women's health [7][25] - The company is positioned to capitalize on the growing demand for women's health solutions, with increasing political and media attention on the subject [30] - Management emphasizes the importance of building real-world data through its commercial model to strengthen future regulatory submissions [27][28] Other Important Information - The company has received significant non-dilutive funding, including approximately $20.8 million from sales of common stock and $13.6 million from the Gates Foundation in 2025 [31] - The company is actively engaging in provider education and digital marketing to raise awareness of its products [12][49] Q&A Session Summary Question: When was your last interaction with FDA on Sildenafil Cream? - Management confirmed that interactions with the FDA occurred last year, focusing on aligning endpoints for the trial [37][38] Question: Do you need to conduct any additional safety studies? - Management stated that existing safety data would be sufficient for submission, emphasizing the localized effect of the topical formulation [43][44] Question: What are you seeing with the order patterns for DARE to PLAY? - Management reported a mix of prescriptions coming in from both brick-and-mortar providers and telehealth channels, indicating strong interest [46][47] Question: How do you envision the bigger driver of volume for DARE to PLAY? - Management is evaluating various platforms and partnerships to ensure effective patient acquisition and reach [57][58] Question: How are you thinking about promoting DARE to RESTORE? - Management plans to leverage digital marketing and provider engagement to create awareness and drive conversion for DARE to RESTORE [51][53]

CORPORATE DECK MARCH 26, 2026 DAREBIOSCIENCE.COM | NASDAQ: DARE ©2026 DARÉ BIOSCIENCE, ALL RIGHTS RESERVED Forward-Looking Statements & Disclaimers This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Daré Bioscience, Inc. ("Daré" or the "Company"). This presentation discusses potential future drug and medical device products that are or will be under clinical or preclinical investigation and have not been approved for use ou ...

Core Viewpoint - The presentation focuses on the introduction of DARE to PLAY, a novel Sildenafil Cream formulation specifically designed for women, highlighting the company's commitment to addressing women's health needs [2]. Group 1: Company Overview - Dare Bioscience is led by CEO Sabrina Martucci Johnson, who emphasizes the company's mission to innovate in women's health [2]. - The company is excited to present DARE to PLAY, which is described as a first-of-its-kind product in the market [2]. Group 2: Product Introduction - DARE to PLAY is a Sildenafil Cream formulated specifically for women, indicating a targeted approach to addressing sexual health issues [2]. - The presentation features insights from Dr. Kingsberg and Dr. Simon, who will provide an overview of the product and its implications for women's health [3].

Core Insights - Daré Bioscience, Inc. has announced the launch of DARE to PLAY Sildenafil Cream, a topical formulation aimed at improving women's sexual arousal, set to be available by prescription in Q4 2025 [1][9] - The product is clinically proven to enhance genital blood flow and sexual response, differentiating it from untested compounded products [2] - A consumer awareness campaign has been initiated in collaboration with Rosy Wellness to educate women about sexual health and the benefits of DARE to PLAY [3][8] Product Details - DARE to PLAY Sildenafil Cream contains sildenafil, the same active ingredient found in Viagra, specifically formulated for women [2] - The product aims to address the long-standing gap in women's sexual health solutions, providing a clinically backed option for those experiencing arousal concerns [2][11] Campaign and Educational Initiatives - The campaign includes the release of educational content and interactive modules designed to inform women about physical arousal and how DARE to PLAY can assist them [3][6] - Quickies, short-form videos reviewed for clinical accuracy, will combat misinformation and provide trustworthy education on female sexual health [4][5] - The Arousal Collection offers a deeper exploration of physical arousal, authored by Dr. Sameena Rahman, to guide women through understanding their sexual health [6][7] Collaboration and Community Engagement - The partnership with Rosy Wellness aims to empower women through evidence-based resources and community support, enhancing access to sexual health information [8][10] - The campaign represents a commitment to advancing sexual health equity and ensuring women have the necessary information and solutions [8] Company Background - Daré Bioscience focuses on addressing unmet needs in women's health, with a portfolio that includes innovative solutions for contraception, sexual health, and menopause [11][12] - The company aims to bring products to market that leverage existing clinical proof of concept, optimizing access for women in a fiscally responsible manner [11]

Core Insights - Daré Bioscience, Inc. has announced a strategic collaboration with Rosy Wellness to support the marketing and awareness campaign for its DARE to PLAY Sildenafil Cream, aimed at enhancing women's sexual health [1][3][4] Company Overview - Daré Bioscience is a biopharmaceutical company focused on women's health, aiming to address unmet needs through innovative solutions [10] - The company is set to start recording revenue in the fourth quarter of 2025 with the launch of DARE to PLAY Sildenafil Cream, a topical formulation of sildenafil citrate [1][2] Product Details - DARE to PLAY Sildenafil Cream is designed to increase local blood flow to genital tissues, addressing female sexual arousal disorder [2][11] - The product is expected to be available by prescription in the U.S. as a compounded drug under Section 503B of the FDCA [2] Collaboration Highlights - The partnership combines Daré's clinical expertise with Rosy's extensive digital reach and community engagement, which includes over 250,000 women [1][3] - The collaboration will focus on educational outreach and destigmatizing conversations around female sexual health [3][5] Market Context - Female sexual health is identified as a significantly underserved area, with 65% of women reporting concerns with arousal [3][4] - The partnership aims to enhance sexual wellness education and access for women, addressing a historically stigmatized topic [5][8]